Skip to main content
OpenTrials
Completed

NCT Number: NCT01450865

Effect of the Kv7-channel Opener Flupirtine on the Excitability of Human Peripheral Myelinated Axons in Vivo

Slow axonal Kv7 potassium channels are found along unmyelinated axons and at the nodes of Ranvier of myelinated axons in peripheral nerve. As such the pharmacological activation of Kv7 channels offers a potential means of reducing the excitability of peripheral axons. To determine whether this is the case for human peripheral myelinated axons, the effect of the Kv7 channel agonist flupirtine on the electrical excitability of A fibres was examined in both isolated segments of human sural nerve in vitro and in motor axons of the median nerve supplying abductor pollicus brevis in vivo. Axonal excitability was assessed in 21 human sural nerve fascicles in vitro and in 20 volunteers in vivo using threshold tracking in QTRAC (© Institute of Neurology, London, UK). Strength-duration time constant, rheobase current, relative refractory period (RRP), post spike superexcitability at 5 and 7 ms and threshold electrotonus over the 90 100 ms period were used as indices of electrical excitability. In addition, suppression of ectopic discharge in a model of upper limb ischaemia.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Multidisciplinary Pain Unit Department of Anaesthesiology University of Munich Pettenkoferstr. 8a

Munich, Bavaria, 80336, Germany

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • voluntarily
  • age > 18 years old

Exclusion criteria

  • current use of medication (e.g. analgetics, antiepileptics, antidepressants, etc.)
  • prevailing organic disease (e.g. diabetes, vascular or neurologic illness, etc.)
  • previous physical trauma of the forearm (e.g. burning, surgery)
  • primary organ failure
  • pregnancy and lactation

Treatment and study plan

flupirtine

Drug

Potassium channel opener (SNEPCO)

Other names: brand names: Trancopal Dolo, Katadolon

Primary outcomes

  1. Axonal Excitability as assessed with QTrac

    Time frame: Change of neuronal excitability from Baseline (before) to two hours after intervention

    The primary outcome parameter of axonal excitability was the relative refractory period (RRP) as assessed with threshold tracking techniques. Strength-duration time constant, rheobase current, refractoriness determined at 2 and 2.5 ms, superexcitability at 7 ms and threshold electrotonus over the 90 100 ms period were used as secondary outcome measures.

Secondary outcomes

  1. Ectopic Discharge

    Time frame: Change of neuronal excitability from Baseline (before) to two hours after intervention

    Further secondary outcome measures were power content for the surface EMG and the ranked summed scores for the McGill pain questionnaire.

Sponsors and collaborators

Lead sponsor

Ludwig-Maximilians - University of Munich

Other

Registry information

Official study title

Evaluation of the Effect of the K+-Channel Opener Flupirtine on the Excitability of Human Peripheral Myelinated Axons in Vivo: a Randomised Controlled Trial

Important dates

Study start
2009
Primary completion
2010
Study completion
2010
First posted
Oct 12, 2011
Registry last updated
Jan 13, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.